We chose an AAV8-based approach to overexpress the PCSK9 gain-of-function mutant D377Y to induce hypercholesterolemia, allowing us to evaluate the impact of PRDM16 ablation at baseline and during lesion development within the same mouse strains. This evidence concerns the gene PCSK9 and Hypercholesterolemia.